Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 17.36 as of 2026-10-06T16:43:22.221Z.
Consensus retrieved: 2026-10-06T13:30:57.879Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T16:43:22.221Z.
Quote observation: 2026-10-06T16:40:22.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e0735a4b96e2b144a1c4082676ac09623fe8f2e34e42ff401d6c9377466895af
Forward PE Ratio (17.36) = Dated Quote Price ($75.59) / Consensus Forward EPS ($4.36)
FORWARD PE RATIO
17.36
SECTOR MEDIAN · HEALTHCARE
19.43
median of 179 covered companies
CURRENT VS SECTOR MEDIAN
-10.65%
vs the sector median at left
LivaNova PLC
Market Cap
$4.15B
Forward PE Ratio
17.36
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| LivaNova PLC (LIVN) | $4.15B | 17.36 |
| AbCellera Biologics Inc. (ABCL)vs › | $4.08B | N/A |
| Relay Therapeutics, Inc. (RLAY)vs › | $4.07B | N/A |
| Edgewise Therapeutics, Inc. (EWTX)vs › | $4.33B | N/A |
| ICU Medical, Inc. (ICUI)vs › | $3.97B | N/A |
| Indivior Pharmaceuticals Inc (INDV)vs › | $4.41B | 8.38 |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.42B | N/A |
| Heartflow, Inc. Common Stock (HTFL)vs › | $4.43B | N/A |
| BillionToOne, Inc. (BLLN)vs › | $4.57B | 125.03 |
| Option Care Health, Inc. (OPCH)vs › | $4.66B | 16.53 |
Trailing P/E
22.3
reported TTM EPS
Forward P/E
17.4
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $4.36 implies +28.6% EPS growth vs the reported trailing $3.39.
At the dated quote price of $75.59, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $4.36 | $4.30 – $4.46 | 6 | 17.4x |
| 2027-12-31 | $4.68 | $4.50 – $4.86 | 6 | 16.2x |
| 2028-12-31 | $5.23 | $4.96 – $5.74 | 5 | 14.5x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
